Background
COVID-19, the widely recognized and highly contagious respiratory tract infection, has had a substantial impact on the field of dermatology since its emergence in 2019. Various skin-related symptoms have been reported in COVID-infected patients, most notably the distinctive purple-red acral rash resembling chilblain lesions, commonly referred to as “COVID toe.” COVID-19 is classified within the viral RNA family category, and similarly, skin-related symptoms have been observed in connection with other RNA viruses.
Aim
This review aims to explore the relationship between RNA viruses and their associated vascular cutaneous manifestations in comparison to those observed in SARS-CoV-2 infected patients.
Methods
A systematic literature review was conducted using the PubMed database and MeSh terms regarding RNA viruses and related skin manifestations.
Results
A total of 3,994 patients diagnosed with COVID-19 presenting with skin rashes were observed. Chilblain-like lesions (CLL) were most frequently observed (30.2%), followed by erythematous maculopapular/morbilliform rashes (9.1%) and urticarial rashes (4.7%). Out of 8,362 patients diagnosed with RNA viruses, more than half of the skin findings reported were erythematous/maculopapular/morbilliform rashes (52.3%), followed by unspecified rashes (11.3%) and purpuric rashes (10.6%).
Conclusion
When comparing RNA viral infections to COVID-19 cases, we observed similarities in reported skin manifestations and their presumed pathways, with many implicated in the pro-inflammatory response. Due to the wide range of cutaneous symptoms associated with RNA viruses and our current limited understanding of their underlying mechanisms, additional research is warranted to investigate the pathology behind viral-induced skin lesions.